FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced that a plixorafenib abstract has been ...

Pasithea Therapeutics Corp. has announced the acceptance of an abstract for a poster presentation at the upcoming American Society for Clinical Oncology (ASCO) Annual Meeting, scheduled for May 30 ...

The Advanced Lateral Flow Conference (ALFC) is now accepting applications for poster presentations at its 2025 event, taking place October 14-15, 2025, at the Hilton La Jolla Torrey Pines in La Jolla, ...

Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...

Abstract and poster presentation details are below: Title: “Phase 1 dose escalation results of the WEE1 inhibitor, azenosertib, in combination with encorafenib and cetuximab in patients with ...

BioAtla (BCAB) announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research to be held at the ...

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients ...

today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design ...